Cystatin C reduces the in vitro formation of soluble Aβ1‐42 oligomers and protofibrils
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
There are an increasing number of genetic and neuropathological observations to suggest that cystatin C, an extracellular protein produced by all nucleated cells, might play a role in the pathophysiology of sporadic Alzheimer's disease (AD). Recent observations indicate that small and large soluble oligomers of the beta-amyloid protein (Abeta) impair synaptic plasticity and induce neurotoxicity in AD. The objective of the present study was to investigate the influence of cystatin C on the production of such oligomers in vitro. Co-incubation of cystatin C with monomeric Abeta1-42 significantly attenuated the in vitro formation of Abeta oligomers and protofibrils, as determined using electron microscopy (EM), dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting, thioflavin T (ThT) spectrofluorimetry and gel chromatography. However, cystatin C did not dissolve preformed Abeta oligomers. Direct binding of cystatin C to Abeta was demonstrated with the formation of an initial 1:1 molar high-affinity complex. These observations suggest that cystatin C might be a regulating element in the transformation of monomeric Abeta to larger and perhaps more toxic molecular species in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 2×
“4) [29,30] and only small amounts are generated in cell cultivation media under ‘‘ADDL’’-forming conditions.”
Background
Cited by
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Self-citationCystatin C modulates cerebral β-amyloidosis
Kaeser, S. A., Herzig, M. C., Coomaraswamy, J., Kilger, E., Selenica, M.-L., Winkler, D. T., Staufenbiel, M., Levy, E., Grubb, A., & Jucker, M. (2007) · Nature Genetics · doi:10.1038/ng.2007.23 · Cited by 150
Self-citationCystatin C in aging and in Alzheimer’s disease
Mathews, P. M., & Levy, E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.003 · Cited by 133
Cystatin C in Alzheimer's disease
Kaur, G., & Levy, E. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00079 · Cited by 116
Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111
Metadata
- Authors
- Selenica, M. L., Wang, X., Ostergaard‐Pedersen, L., Westlind‐Danielsson, A., & Grubb, A.
- Venue
- Scandinavian Journal of Clinical and Laboratory Investigation
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 67
- Issue
- 2
- Pages
- 179-190
- ISSN
- 0036-5513 (ISSN-L)
- 1502-7686
- OpenAlex
- W1998096679
- Cited by
- 71
- References
- 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystatin C reduces the in vitro formation of soluble Aβ1‐42 oligomers and protofibrils. https://app.cochat.ai/papers/10.1080/00365510601009738
- The paper
- Selenica, M. L., Wang, X., Ostergaard‐Pedersen, L., Westlind‐Danielsson, A., & Grubb, A. (2007). Cystatin C reduces the in vitro formation of soluble Aβ1‐42 oligomers and protofibrils. Scandinavian Journal of Clinical and Laboratory Investigation. https://doi.org/10.1080/00365510601009738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.